4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immatics N.V. (IMTX) operates in the Biotechnology industry and is headquartered in Tübingen, Germany with about 678 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, IMTX reported $48M in revenue and ($196M) in net income.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Interactive charts & full statements → Open the IMTX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $48M | $156M | $54M | $173M | — |
| Operating Income (EBIT) | ($182M) | ($39M) | ($102M) | $30M | — |
| Net Income | ($196M) | $15M | ($95M) | $28M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $8M | $20M | $5M | $5M | $19M |
| Operating Income (EBIT) | ($66M) | ($39M) | ($55M) | ($53M) | ($35M) |
| Net Income | ($58M) | ($36M) | ($50M) | ($70M) | ($40M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $562M | $696M | $510M | $408M | — |
| Total Liabilities | $78M | $121M | $292M | $204M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMTX viewer.
About TickerBase · Data methodology & sources